Impact Biomedical (IBO) Invested Capital (2022 - 2025)

Impact Biomedical (IBO) has reported Invested Capital for 4 consecutive years, with $34.0 million the latest figure, recorded in Q3 2025.

• For the quarter ending Q3 2025, Invested Capital fell 19.84% year-over-year to $34.0 million; the trailing twelve-month figure through Sep 2025 stood at $34.0 million (down 19.84% YoY), and the FY2024 full-year result was $4.0 billion, up 7572.11% from the prior year.
• Invested Capital declined to $34.0 million in Q3 2025 per IBO's latest filing, from $37.3 million in the prior quarter.
• Across five years, Invested Capital topped out at $52.4 million in Q4 2023 and bottomed at $25.1 million in Q1 2025.
• Historically, Invested Capital has averaged $38.7 million across 4 years, with a median of $40.1 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Invested Capital grew 22.86% in 2023, then tumbled 46.21% in 2024.
• Over 4 years, Invested Capital stood at $42.7 million in 2022, then gained by 22.86% to $52.4 million in 2023, then sank by 46.21% to $28.2 million in 2024, then gained by 20.45% to $34.0 million in 2025.
• According to Business Quant data, Invested Capital over the past three periods registered $34.0 million, $37.3 million, and $25.1 million for Q3 2025, Q2 2025, and Q1 2025 respectively.